A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002)

Conditions: Tumor Infiltrating Lymphocytes; Safety; Melanoma; Efficacy; Adverse Drug Event Interventions: Biological: GC101 TIL Sponsors: Shanghai Juncell Therapeutics Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials